Subscribe To
Roche's (rhhby) lunsumio application gets priority review
Roche's (RHHBY) BLA application seeking approval for the use of Lunsumio for relapsed or refractory fol...
July 6, 2022, 2:45 pm
Fate: possible speedy fda approval process with rmat designation
Meeting with FDA set for mid-2022 to discuss potential to begin pivotal trial using FT516 for patients with re...
June 3, 2022, 12:52 pm
Biomea fusion to present new preclinical data showing bmf-219's strong activity in relapsed/refractory chronic lymphocytic leukemia (cll) tumor models at asco 2022
REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to dis...
May 26, 2022, 6:30 pm
Fda places clinical hold on foghorn therapeutics' early-stage blood cancer trial
The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's (NASDAQ: FHTX) Phase 1 dose-escalation study of FHD-286 in ...
May 20, 2022, 6:38 am
Springworks therapeutics: rating buy ahead of mid-year data releases
Data from Phase 3 trial for Nirogacestat in treating desmoid tumors and Phase 2 combination trial with anti-BCMA antibody Blenrep in ...
May 2, 2022, 5:42 pm
Lava therapeutics to present updated lava-051 clinical data at the 2022 american society of clinical oncology (asco) annual meeting
UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focu...
April 27, 2022, 10:05 am
Gracell biotechnologies to present data at aacr annual meeting 2022 showcasing early first-in-human results for gc502 in r/r b-all
Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL PALO ALTO, Calif. and...
April 8, 2022, 4:00 pm
Bristol myers (bmy) gets ec nod for car t cell therapy breyanzi
The European Commission grants marketing authorization to Bristol Myers' (BMY) Breyanzi for treating certain forms of ...
April 6, 2022, 1:33 pm
Curis plummets to 52-week low after fda clinical hold on blood cancer trial
The FDA has placed a partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2a study in ...
April 4, 2022, 9:10 am
Why are tc biopharm shares trading higher today
The FDA has granted Orphan Drug designation to TC Biopharm Ltd's (NASDAQ: TCBP) lead product OmnImmune for use in Acute Myeloid Leukemia. After ...
March 17, 2022, 11:51 am
Caribou biosciences to present preclinical data on cb-011, an immune-cloaked allogeneic anti-bcma car-t cell therapy, at the american association for cancer research (aacr) annual meeting
BERKELEY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharm...
March 8, 2022, 8:19 pm
Fda slams brakes on legend biotech's car-t therapy trial in lymphoma patients
The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901. LB1901 is the company's investig...
February 15, 2022, 9:39 am
Fda slams brakes on legend biotech's car-t therapy trial in lymphoma patients
The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901. LB1901 is the company's investig...
February 15, 2022, 9:39 am
Fda slams brakes on legend biotech's car-t therapy trial in lymphoma patients
The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901. LB1901 is the company's investig...
February 15, 2022, 9:39 am
Moleculin biotech annamycin doublet therapy shows 68% overall survival in animal study
Moleculin Biotech Inc (NASDAQ: MBRX) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, ...
February 14, 2022, 2:10 pm
Moleculin biotech annamycin doublet therapy shows 68% overall survival in animal study
Moleculin Biotech Inc (NASDAQ: MBRX) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, ...
February 14, 2022, 2:10 pm
Moleculin biotech annamycin doublet therapy shows 68% overall survival in animal study
Moleculin Biotech Inc (NASDAQ: MBRX) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, ...
February 14, 2022, 2:10 pm
Fda lifts partial hold on kura oncology's early-stage leukemia trial
The FDA has lifted the partial clinical hold on Kura Oncology Inc (NASDAQ: KURA) KOMET-001 Phase 1b study of KO-539 in patients with ...
January 21, 2022, 5:49 am
Fda lifts partial hold on kura oncology's early-stage leukemia trial
The FDA has lifted the partial clinical hold on Kura Oncology Inc (NASDAQ: KURA) KOMET-001 Phase 1b study of KO-539 in patients with ...
January 21, 2022, 5:49 am
Fda lifts partial hold on kura oncology's early-stage leukemia trial
The FDA has lifted the partial clinical hold on Kura Oncology Inc (NASDAQ: KURA) KOMET-001 Phase 1b study of KO-539 in patients with ...
January 21, 2022, 5:49 am